Scope and claims analysis for US Patent 11,357,741 (CBD for focal seizures in Dravet Syndrome) and the US patent landscape
US Patent 11,357,741 is a US method-of-treatment patent covering administration of a highly purified cannabidiol (CBD) drug substance with defined purity and dosing ranges to treat focal seizures in patients with Dravet syndrome. The claims are framed around (1) indication and seizure phenotype, (2) CBD purity, (3) dose initiation and titration to a maximum daily mg/kg dose, and (4) content limits on THC (including optional CBDV), plus (5) compatibility with concomitant anti-epileptic drugs (AED) lists and (6) optional CBD source (highly purified cannabis extract vs synthetic CBD).
The practical patent “fence” is narrow in subject matter (a defined treatment method for a specific patient population) but broad in operational variables that can be configured by a manufacturer: purity level (≥98% w/w), allowable THC content (≤0.15% w/w), dosing range (about 5 to about 25 mg/kg/day), optional CBDV presence (up to 1% w/w), and permitted concomitant AEDs.
What does US Patent 11,357,741 claim, and what is the method scope for CBD in Dravet syndrome?
Short answer: The patent claims a method of treating focal seizures in Dravet syndrome by administering CBD (purity ≥98% w/w) at about 5–25 mg/kg/day, with dependent claim fences around impairment subtype, treatment-resistant disease, titration increments, THC content limits, CBDV content, CBD source (synthetic vs cannabis extract), and specific concomitant AED selections.
Core claim elements that define coverage
Claim 1 (independent):
- Patient/indication: “focal seizures in Dravet Syndrome”
- Disease state (broadly): not required in claim 1 but added in dependent claims (treatment-resistant)
- Active: “cannabidiol (CBD) drug substance”
- Purity: at least 98% (w/w)
- Dose range: about 5 mg/kg/day to about 25 mg/kg/day
- Treatment format: “administering to a subject in need thereof a drug product comprising” the CBD drug substance
Claim 16 (independent):
- Similar, but adds a specific titration architecture:
- start: 5 mg/kg/day
- increase: by 2 to 5 mg/kg increments
- up to: 25 mg/kg/day
- Claim 16 also contains an important distinction vs claim 1: the method explicitly includes THC content as a pathway option through a dependent claim (claim 19–20) rather than being structurally required in the independent.
Seizure phenotype and Dravet patient subgroups
Dependent claim 2: focal seizures with impairment
Dependent claim 3: Dravet syndrome is treatment-resistant
These dependencies matter because a competitor may attempt to argue non-infringement if their clinical protocol is framed around a different seizure phenotype or different population criteria. Still, the independent claims do not require “impairment” or “treatment-resistant,” so non-infringement arguments face an uphill climb unless the product is clearly used outside the claimed method.
Product attribute coverage: purity, THC, CBDV, and source
Dependent claim 5: CBD is “a highly purified extract of cannabis”
Dependent claim 6: extract has <0.15% THC
Dependent claim 7: extract includes up to 1% (w/w) CBDV
Dependent claim 8: CBD is “synthetic compound”
This is a key scope point: the patent contemplates at least two distinct drug-substance sourcing paradigms:
- highly purified cannabis extract with controlled THC and optional CBDV, and
- synthetic CBD
That means generic design-arounds that rely only on “synthetic vs botanical” are unlikely to avoid coverage if the method still administers CBD with ≥98% purity at the claimed dosing ranges.
Combination therapy and concomitant AED list
Dependent claim 4: CBD administered with one or more concomitant AEDs
Dependent claim 9: AEDs selected from a long enumerated list
Dependent claim 27 and 28: repeat the combination therapy concept with another enumerated subset/list that includes many of the same agents, such as:
- valproic acid, clobazam, stiripentol, levetiracetam, lamotrigine, topiramate
- carbamazepine, phenobarbital, phenytoin
- rufinamide, lacosamide, zonisamide
- benzodiazepines and related seizure meds
- and even “ketogenic diet” and “vagus nerve stimulation” are listed as items within the AED group
This drafting approach makes infringement more likely where the CBD regimen is used “with common Dravet standard-of-care AEDs,” because the claim does not require a specific disease control outcome. It only requires concomitance.
Dose titration granularities
Independent claim 1 sets a range (about 5 to about 25 mg/kg/day). Dependent claim 10–15 then anchor specific dose points: 10, 12, 14, 15, 18, 20 mg/kg/day.
Independent claim 16 sets an administration scheme:
- start at 5 mg/kg/day
- titrate up by 2–5 mg/kg increments
- up to 25 mg/kg/day
This is important for product and label-driven risk. If a manufacturer’s dosing instructions align with any of these dose points and titration logic, it can trigger method coverage even if the marketing label does not mirror the claim verbatim.
Which claims are likely to be most infringement-relevant: the dose range or the purity/THC limits?
Short answer: The dose range (5–25 mg/kg/day) and purity threshold (≥98% w/w) are the most operationally decisive elements in independent claims. THC and CBDV restrictions tighten the “extract” embodiment in dependent claims, but because those restrictions are not required in the independent claims you still face risk if a court reads the independent claims broadly.
How courts tend to view “purity” and “dose” in method claims
A method claim like claim 1 or claim 16 is typically infringed when the accused regimen requires:
- administering a CBD drug substance meeting the defined purity, and
- administering within the defined mg/kg regimen, and
- treating the claimed patient/indication (focal seizures in Dravet).
Thus, even if a competitor uses a CBD source with low THC, infringement can still occur if the purity and dose regimen fall within the independent claim. The THC and CBDV elements mostly matter when assessing dependent claim scope or when arguing that the marketed product and prescribing protocol do not match claim-specific embodiments.
Practical risk matrix by design knob
| Design feature |
Claim dependence |
Does it avoid independent coverage? |
Key impact |
| CBD purity ≥98% (w/w) |
required (claims 1,16) |
No |
Core fence |
| CBD dose within ~5–25 mg/kg/day |
required (claims 1,16) |
No |
Core fence |
| Start at 5 mg/kg/day then increments 2–5 mg/kg |
required for claim 16 only |
Avoids claim 16 if not used |
Alters risk by regimen design |
| THC ≤0.15% (w/w) |
dependent (claims 19–20 via claim 5/6 path) |
Not needed for claim 1 |
Helps only against dependent embodiments |
| CBDV up to 1% (w/w) |
dependent (claim 7) |
Not needed |
Helps only against dependent embodiments |
| Synthetic vs cannabis extract |
dependent (claim 8 vs 5) |
Not needed for claim 1 |
Source alone may not avoid |
| Concomitant AEDs (with enumerated list) |
dependent (claims 4,9,27,28) |
Not needed for claim 1 |
Main risk increases when label mirrors combo use |
| Focal seizures with impairment |
dependent (claim 2) |
Not needed for claim 1 |
Only affects that dependent coverage |
| Treatment-resistant |
dependent (claim 3) |
Not needed for claim 1 |
Only affects dependent coverage |
What is the claimed THC limit, and how does it shape extract-based CBD product design?
Short answer: The patent has dependent embodiments allowing cannabis extract with THC content below 0.15% w/w, and optional CBDV up to 1% w/w.
THC guardrails in the claims provided
- Claim 6: “less than 0.15% tetrahydrocannabinol (THC)” for the “highly purified extract of cannabis” embodiment.
- Claim 19–20: “CBD comprises Δ9-THC” and “not more than 0.15% (w/w) Δ9-THC.”
Interpretation implications for formulation strategies
If a product has CBD purity ≥98% w/w but THC content exceeds 0.15% w/w, then dependent claim embodiments keyed to THC limits are less likely to be met. But independent claim 1 and 16 do not require THC limits in the text you supplied. That means a design that fails the THC cap does not automatically clear the independent claims.
How broad is the dose coverage: what timelines and dose points are explicitly claimed?
Short answer: The patent covers an overall dose range about 5–25 mg/kg/day (independent claims) and also claims specific intermediate dose levels and a structured titration plan.
Explicit dose anchors (dependent claims)
The provided claims expressly recite:
- about 10 mg/kg/day (claims 10,21)
- about 12 mg/kg/day (claims 11,22)
- about 14 mg/kg/day (claims 12,23)
- about 15 mg/kg/day (claims 13,24)
- about 18 mg/kg/day (claims 14,25)
- about 20 mg/kg/day (claims 15,26)
Independent dosing mechanics
- Claim 1: CBD administered at about 5 mg/kg/day to about 25 mg/kg/day
- Claim 16: start 5 mg/kg/day, then increase by 2 to 5 mg/kg increments, up to 25 mg/kg/day
This combination creates two vectors for infringement:
- a range-based regimen that hits any point in the interval, and
- a titration regimen that matches the increment rules even if the final daily dose is the same.
What patent landscape typically surrounds CBD for Dravet syndrome in the US?
Short answer: US CBD Dravet/IP landscapes usually stack across three layers: (1) formulation/composition patents (purity, THC control, impurities, delivery), (2) method-of-use patents (indication and dosing regimens), and (3) process/manufacturing patents (purification, isolation, source material). US Patent 11,357,741 is positioned as a method-of-treatment patent centered on purity- and dose-defined administration for focal seizures in Dravet syndrome.
Likely clusters relevant to this claim scope
Even without the full patent family and prosecution history for 11,357,741, the claim architecture strongly maps to common CBD Dravet claim clusters:
- Purified CBD composition: purity thresholds like ≥98% w/w
- Low-THC extracts: THC caps such as 0.15% w/w and impurity profiles
- Dosing regimens: mg/kg/day windows and titration increments
- Population/indication: Dravet syndrome and focal seizures, sometimes treatment-resistant subgroups
- Combination therapy: concomitant AEDs lists
A competitor clearance exercise typically needs to check whether a potential generic or alternative manufacturer’s product label and real-world prescribing could be construed to practice any dosing regimen within the claimed interval and purity attributes.
How to think about claim overlap with other CBD Dravet patents
Because these claims use purity and mg/kg dosing rather than formulation excipients, they can overlap with:
- composition patents that define “what CBD is” and
- label/dosing patents that define “how it is used.”
That means even if a competitor designs around purity or THC in composition claims, the method claims can still capture the regimen if purity and dose align.
How does US 11,357,741 compare with typical CBD-drug label dosing and Dravet treatment protocols?
Short answer: The claimed dose window and titration architecture are designed to align with pediatric dosing practices for CBD in epilepsy, increasing the likelihood that prescribing under US labeling or compendia regimens could land inside the claimed mg/kg parameters.
Why the “about” language matters
The claims use “about” and range-based dose boundaries. That drafting style tends to reduce the ability to avoid infringement by small deviations in dose.
Why “titration increments” matter
A regimen that starts at 5 mg/kg/day and increases by 2–5 mg/kg increments is a direct operational match to claim 16. Regimens outside that exact increment logic may reduce claim 16 risk but may still fall within claim 1 if the overall dose remains in the range.
What are the main US design-around levers against this patent?
Short answer: The most credible levers are to avoid one of the independent claim’s hard requirements: (a) CBD purity ≥98% w/w and/or (b) dosing within about 5–25 mg/kg/day in a regimen treating focal seizures in Dravet syndrome. Adjusting only THC below 0.15% or switching synthetic vs extract may not clear independent claim risk.
Lever analysis by claim element
- Purity (≥98% w/w): The clearest but also the hardest lever to change while maintaining an acceptable clinical product. If purity is below 98% w/w, claims 1 and 16 are harder to meet.
- Dose range (~5–25 mg/kg/day): If the regimen is consistently below ~5 mg/kg/day or above ~25 mg/kg/day (not likely clinically), independent claim risk drops.
- Indication framing: Using CBD for a different indication or a different seizure category not captured as “focal seizures in Dravet syndrome” can reduce infringement risk, but practical enforcement often focuses on real-world use and evidence.
- Combination therapy: Stopping concomitant AED usage may reduce dependent claim exposure (claims 4,9,27,28), but independent claims still remain.
What does this mean for generic entry and Paragraph IV-type litigation risk in the US?
Short answer: If an FDA ANDA/505(b)(2) strategy relies on an approved CBD product’s label dosing that falls inside ~5–25 mg/kg/day and uses a CBD drug substance with ≥98% w/w purity, it is exposed to method-of-use infringement theories. The presence of dependent claims on THC and CBDV can give some formulation optionality but does not eliminate independent method risk.
Where litigation is likely to center
- Purity evidence: testing data for the active ingredient batch and stability studies
- Dose evidence: label instructions, titration schedule, physician practice, and distribution records
- Patient population evidence: Dravet diagnosis and seizure phenotype documentation
- Source evidence: cannabis extract vs synthetic CBD can be disputed but may not defeat independent claims
Patent estate strength: how “tight” is the claim coverage from the text provided?
Short answer: Coverage is tight on two independent parameters (purity and dosing range). It is moderately broad on clinical framing (focal seizures in Dravet syndrome) and broad on combination AED list only in dependent claims. It is narrow on some subpopulations via dependencies (impairment, treatment-resistant).
Net assessment from the provided claim set
- High fence strength on purity and dose.
- Medium fence strength on seizure phenotype because the independent claims already capture “focal seizures” broadly.
- Lower fence strength on THC and CBDV because they appear in dependent claims (not in claim 1/16 as provided).
- Moderate exposure to regimen titration details because claim 16 adds structured dosing increments beyond the general range.
Key Takeaways
- US Patent 11,357,741 covers a method of treating focal seizures in Dravet syndrome using CBD with purity ≥98% (w/w).
- The independent method-of-use claims target CBD dosing about 5 to about 25 mg/kg/day (claim 1) and a start-at-5 with 2–5 mg/kg increments titration to 25 mg/kg/day (claim 16).
- Dependent claim scope adds fences for focal seizures with impairment, treatment-resistant Dravet, and concomitant AED therapy with an enumerated list.
- The patent includes dependent embodiments for THC ≤0.15% (w/w) and CBDV up to 1% (w/w), plus alternate embodiments for cannabis extract vs synthetic CBD.
- Design-arounds that only alter THC content or CBD source may not avoid the independent claims; the most impactful levers are avoiding ≥98% purity CBD and/or avoiding dosing within ~5–25 mg/kg/day in the targeted Dravet focal-seizure population.
FAQs
1. Does US Patent 11,357,741 require THC control in the independent method claims?
No. Based on the claim text provided, THC caps (≤0.15% w/w) appear in dependent claims, while independent claims require CBD purity ≥98% (w/w) and dosing within the stated mg/kg ranges.
2. What dosing structure is explicitly protected beyond the general dose range?
Claim 16 explicitly protects starting at 5 mg/kg/day, increasing by 2–5 mg/kg increments, and reaching up to 25 mg/kg/day.
3. Are concomitant AEDs required to infringe the independent claims?
No. Concomitant AED requirements appear in dependent claims (claims 4 and 27), while independent claims are not limited to combination therapy.
4. Can a synthetic CBD product avoid the patent?
Switching to synthetic CBD only addresses dependent embodiments (e.g., claim 8 vs claim 5). Independent claims are still met if the CBD purity and dosing regimen match.
5. Which claim elements are most likely to be proven with laboratory and clinical records in litigation?
CBD purity (≥98% w/w) and the administered dosing regimen (mg/kg/day and titration steps), paired with patient diagnosis and seizure phenotype documentation for Dravet focal seizures.
References
- US Patent 11,357,741 (claims as provided by user).
